The use of G-protein coupled receptor models in lead optimization

Future Medicinal Chemistry

Volumn 3, Issue 6, 2011, Pages 709-721

  Tautermann, Christofer S ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR;

BINDING AFFINITY; COMPUTER MODEL; CRYSTAL STRUCTURE; DRUG RESEARCH; HUMAN; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

DRUG DESIGN; HIGH-THROUGHPUT SCREENING ASSAYS; MODELS, MOLECULAR; RECEPTORS, G-PROTEIN-COUPLED; SMALL MOLECULE LIBRARIES;

EID: 79955956206     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.24     Document Type: Review

References (124)

1. Lagerstrom MC, Schioth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat. Rev. Drug Discov. 7(4), 339-357 (2008).
2. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63(6), 1256-1272 (2003).
3. Chung S, Funakoshi T, Civelli O. Orphan GPCR research. Br. J. Pharmacol. 153(Suppl. 1), S339-S346 (2008). (Pubitemid 351341000)
4. Lin SH, Civelli O. Orphan G protein-coupled receptors: targets for new therapeutic interventions. Ann. Med. 36(3), 204-214 (2004). (Pubitemid 38680197)
5. Vauquelin G, von Mentzer B. G Protein- Coupled Receptors. John Wiley & Sons Ltd, Chichester, UK (2007).
6. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K. The 7 TM G-protein-coupled receptor target family. ChemMedChem 1(8), 760-782 (2006).
7. G Protein-Coupled Receptors as Drug Targets. Seifert R, Wieland T (Eds).Wiley-VCH, Weinheim, Germany (2005).
8. Fredholm BB, Hökfelt T, Milligan G. G-protein-coupled receptors: an update. Acta Physiol. 190(1), 3-7 (2007). (Pubitemid 46570172)
9. de la Nuez Veulens A, Rodriguez R. G protein-coupled receptors as targets for drug design. Biotechnol. Apl. 26, 24-33 (2009).
10. Lundstrom K. Latest development in drug discovery on G protein-coupled receptors. Curr. Protein Pept. Sci. 7(5), 465-470 (2006). (Pubitemid 44524494)
11. Klebe G. Drug Design: Methodology, Concepts, and Mode-of-Action. Springer (2011).
12. Brinks HL, Eckhart AD. Regulation of GPCR signaling in hypertension. Biochim. Biophys. Acta 1802(12), 1268-1275 (2010).
13. Kobayashi NR, Hawes SM, Crook JM, Pebay A. G-protein coupled receptors in stem cell self-renewal and differentiation. Stem Cell Rev. 6(3), 351-366 (2010).
14. Smith TH, Sim-Selley LJ, Selley DE. Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br. J. Pharmacol. 160(3), 454-466 (2010).
15. Dowal L, Flaumenhaft R. Targeting platelet G-protein coupled receptors (GPCRs): looking beyond conventional GPCR antagonism. Curr. Vasc. Pharmacol. 8(2), 140-154 (2010).
16. Jacobson KA. Introduction to adenosine receptors as therapeutic targets. Handb. Exp. Pharmacol. 193, 1-24 (2009).
17. Rengo G, Lymperopoulos A, Koch WJ. Future G protein-coupled receptor targets for treatment of heart failure. Curr. Treat. Options Cardiovasc. Med. 11(4), 328-338 (2009).
18. Wang K, Wong YH. G Protein signaling controls the differentiation of multiple cell lineages. Biofactors 35(3), 232-238 (2009).
19. Okayama Y, Saito H, Rai C. Targeting human mast cells expressing G-protein-coupled receptors in allergic diseases. Allergol. Int. 57(3), 197-203 (2008).
20. Jin T, Xu X, Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine 44(1), 1-8 (2008).
21. Fraser CC. G protein-coupled receptor connectivity to NF-kB in inflammation and cancer. Int. Rev. Immunol. 27(5), 320-350 (2008).
22. Galliera E, Corsi MM, Bonecchi R, Locati M, Mantovani A. Chemokines as pharmacological targets. Mini Rev. Med. Chem. 8(7), 638-646 (2008).
23. Lee HJ, Wall B, Chen S. G-protein-coupled receptors and melanoma. Pigment Cell Melanoma Res. 21(4), 415-428 (2008). (Pubitemid 351990969)
24. Lim WK. GPCR drug discovery: novel ligands for CNS receptors. Recent Pat. CNS Drug Discov. 2(2), 107-112 (2007). (Pubitemid 46952448)
25. Allen SJ, Crown SE, and Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu. Rev. Immunol. 25, 787-820 (2007) (Pubitemid 46697924)
26. Hill SJ. G-protein-coupled receptors: past, present and future. Br. J. Pharmacol. 147(Suppl. 1), S27-S37 (2006). (Pubitemid 43077259)
27. Cherezov V, Rosenbaum DM, Hanson MA et al. High-resolution crystal structure of an engineered human b2-adrenergic G protein coupled receptor. Science 318(5854), 1258-1265 (2007). (Pubitemid 350172884)
28. Rasmussen SGF, Choi HJ, Rosenbaum DM et al. Crystal structure of the human b2 adrenergic G-protein-coupled receptor. Nature 450(7168), 383-387 (2007). (Pubitemid 350126755)
29. Rasmussen SGF, Choi HJ, Fung JJ et al. Structure of a nanobody-stabilized active state of the b2 adrenoceptor. Nature 469(7329), 175-180 (2011).
30. Warne T, Serrano-Vega MJ, Baker JG et al. Structure of a b1-adrenergic G-protein-coupled receptor. Nature 454(7203), 486-491 (2008).
31. Warne T, Moukhametzianov R, Baker JG et al. The structural basis for agonist and partial agonist action on a b1-adrenergic receptor. Nature 469(7329), 241-244 (2011).
32. Jaakola VP, Griffith MT, Hanson MA et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322(5905), 1211-1217 (2008).
33. Wu B, Chien EY, Mol CD et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330(6007), 1066-1071 (2010).
34. Chien EYT, Liu W, Zhao Q et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330(6007), 1091-1095 (2010).
35. Palczewski K, Kumasaka T, Hori T et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289(5480), 739-745 (2000). (Pubitemid 30650186)
36. Murakami M, Kouyama T. Crystal structure of squid rhodopsin. Nature 453(7193), 363-367 (2008). (Pubitemid 351693128)
37. Costanzi S, Siegel J, Tikhonova IG, Jacobson KA. Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. Curr. Pharm. Des. 15(35), 3994-4002 (2009).
38. Archer E, Maigret B, Escrieut C, Pradayrol L, Fourmy D. Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? Trends Pharmacol. Sci. 24(1), 36-40 (2003). (Pubitemid 36009288)
39. Bissantz C, Bernard P, Hibert M, Rognan D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins 50(1), 5-25 (2003). (Pubitemid 36090604)
40. Kimura SR, Tebben AJ, Langley DR. Expanding GPCR homology model binding sites via a balloon potential: a molecular dynamics refinement approach. Proteins 71(4), 1919-1929 (2008). (Pubitemid 351732945)
41. Mobarec JC, Sanchez R, Filizola M. Modern homology modeling of G-protein coupled receptors: which structural template to use? J. Med. Chem. 52(16), 5207-5216 (2009).
42. Shacham S, Marantz Y, Bar-Haim S et al. PREDICT modeling and in-silico screening for G-protein coupled receptors. Proteins 57(1), 51-86 (2004). (Pubitemid 39195884)
43. Vaidehi N, Floriano WB, Trabanino R et al. Prediction of structure and function of G protein-coupled receptors. Proc. Natl Acad. Sci. USA 99(20), 12622-12627 (2002).
44. Filizola M, Perez JJ, Carteni-Farina M. BUNDLE: a program for building the transmembrane domains of G-protein-coupled receptors. J. Comput. Aided Mol. Des. 12(2), 111-118 (1998). (Pubitemid 128691445)
45. Rayan A. New vistas in GPCR 3D structure prediction. J. Mol. Model. 16(2), 183-191 (2010).
46. Tebben AJ, Schnur DM. Beyond rhodopsin: G protein-coupled receptor structure and modeling incorporating the b2-adrenergic and adenosine A2A crystal structures. Chemoinformatics and Computational Chemical Biology. Methods Mol. Biol. 359-386 (2011).
47. Vaidehi N. Dynamics and flexibility of G-protein-coupled receptor conformations and their relevance to drug design. Drug Discov. Today 15(21-22), 951-957 (2010).
48. Perez DM, Karnik SS. Multiple signaling states of G-protein-coupled receptors. Pharmacol. Rev. 57(2), 147-161 (2005). (Pubitemid 41043881)
49. Claing A, Laporte SA. Novel roles for arrestins in G protein-coupled receptor biology and drug discovery. Curr. Opin. Drug Discov. Devel. 8(5), 585-589 (2005). (Pubitemid 41224121)
50. Bhattacharya S, Vaidehi N. Computational mapping of the conformational transitions in agonist selective pathways of a G-protein coupled receptor. J. Am. Chem. Soc. 132(14), 5205-5214 (2010).
51. Tautermann CS and Pautsch A. The implication of the first agonist bound activated GPCR X-ray structure on GPCR in silico modeling. ACS Med. Chem. Lett. DOI: 10.1021/ml100247s (2011) (Epub ahead of print).
52. Bleicher KH, Bohm HJ, Muller K. Alanine AI: hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. 2(5), 369-378 (2003). (Pubitemid 37361707)
53. Bluml K, Mutschler E, Wess J. Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J. Biol. Chem. 269(29), 18870-18876 (1994). (Pubitemid 24226200)
54. Goodwin JA, Hulme EC, Langmead CJ, Tehan BG. Roof and floor of the muscarinic binding pocket: variations in the binding modes of orthosteric ligands. Mol. Pharmacol. 72(6), 1484-1496 (2007). (Pubitemid 350146086)
55. Hamdan FF, Ward SD, Siddiqui NA, Bloodworth LM, Wess J. Use of an in situ disulfide cross-linking strategy to map proximities between amino acid residues in transmembrane domains I and VII of the M3 muscarinic acetylcholine receptor. Biochemistry 41(24), 7647-7658 (2002). (Pubitemid 34627792)
56. Huang XP, Nagy PI, Williams FE, Peseckis SM, Messer WS Jr. Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors. Br. J. Pharmacol. 126(3), 735-745 (1999). (Pubitemid 29087854)
57. Huang XP, Williams FE, Peseckis SM, Messer WS Jr. Differential modulation of agonist potency and receptor coupling by mutations of Ser388Tyr and Thr389Pro at the junction of transmembrane domain VI and the third extracellular loop of human M(1) muscarinic acetylcholine receptors. Mol. Pharmacol. 56(4), 775-783 (1999). (Pubitemid 29491180)
58. Hulme EC, Lu ZL, Saldanha JW, Bee MS. Structure and activation of muscarinic acetylcholine receptors. Biochem. Soc. Trans. 31(Pt. 1), 29-34 (2003). (Pubitemid 36241392)
59. Krejci A, Tucek S. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol. Pharmacol. 60(4), 761-767 (2001). (Pubitemid 32900258)
60. Lebon G, Langmead CJ, Tehan BG, Hulme EC. Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol. Pharmacol. 75(2), 331-341 (2009).
61. Li B, Scarselli M, Knudsen CD et al. Rapid identification of functionally critical amino acids in a G protein-coupled receptor. Nat. Methods 4(2), 169-174 (2007). (Pubitemid 46454686)
62. Lu ZL, Saldanha JW, Hulme EC. Transmembrane domains 4 and 7 of the M(1) muscarinic acetylcholine receptor are critical for ligand binding and the receptor activation switch. J. Biol. Chem. 276(36), 34098-34104 (2001).
63. Prilla S, Schrobang J, Ellis J, Holtje HD, Mohr K. Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol. Pharmacol. 70(1), 181-193 (2006).
64. Schmidt C, Li B, Bloodworth L, Erlenbach I, Zeng FY, Wess J. Random mutagenesis of the M3 muscarinic acetylcholine receptor expressed in yeast. Identification of point mutations that 'silence' a constitutively active mutant M3 receptor and greatly impair receptor/G protein coupling. J. Biol. Chem. 278(32), 30248-30260 (2003). (Pubitemid 36962419)
65. Vogel WK, Sheehan DM, Schimerlik MI. Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: the significance of Tyr403 in the binding of agonists and functional coupling. Mol. Pharmacol. 52(6), 1087-1094 (1997). (Pubitemid 28013728)
66. Ward SD, Curtis CA, Hulme EC. Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. Mol. Pharmacol. 56(5), 1031-1041 (1999).
67. Ward SD, Hamdan FF, Bloodworth LM, Wess J. Conformational changes that occur during M3 muscarinic acetylcholine receptor activation probed by the use of an in situ disulfide cross-linking strategy. J. Biol. Chem. 277(3), 2247-2257 (2002). (Pubitemid 34968812)
68. Wess J, Gdula D, Brann MR. Site-directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. EMBO J. 10(12), 3729-3734 (1991). (Pubitemid 21905400)
69. Wess J, Maggio R, Palmer JR, Vogel Z. Role of conserved threonine and tyrosine residues in acetylcholine binding and muscarinic receptor activation. A study with m3 muscarinic receptor point mutants. J. Biol. Chem. 267(27), 19313-19319 (1992).
70. Evers A, Klabunde T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the a1A adrenergic receptor. J. Med. Chem. 48(4), 1088-1097 (2005). (Pubitemid 40270452)
71. Klabunde T, Hessler G. Drug design strategies for targeting G-protein-coupled receptors. Chembiochem. 3(10), 928-944 (2002). (Pubitemid 35189597)
72. Klabunde T, Giegerich C, Evers A. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. J. Med. Chem. 52(9), 2923-2932 (2009).
73. Oshiro C, Bradley EK, Eksterowicz J et al. Performance of 3D-database molecular docking studies into homology models. J. Med. Chem. 47(3), 764-767 (2004). (Pubitemid 38129734)
74. McRobb FM, Capuano B, Crosby IT, Chalmers DK, Yuriev E. Homology modeling and docking evaluation of aminergic G protein-coupled receptors. J. Chem. Inf. Model. 50(4), 626-637 (2010).
75. Becker OM, Marantz Y, Shacham S et al. G protein-coupled receptors: in silico drug discovery in 3D. Proc. Natl Acad. Sci. USA 101(31), 11304-11309 (2004). (Pubitemid 39038342)
76. Becker OM, Dhanoa DS, Marantz Y et al. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. J. Med. Chem. 49(11), 3116-3135 (2006). (Pubitemid 43830511)
77. Chen JZ, Wang J, Xie XQ. GPCR structure-based virtual screening approach for CB2 antagonist search. J. Chem. Inf. Model. 47(4), 1626-1637 (2007). (Pubitemid 47210066)
78. Evers A, Hessler G, Matter H, Klabunde T. Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. J. Med. Chem. 48(17), 5448-5465 (2005). (Pubitemid 41209243)
79. Kellenberger E, Springael JY, Parmentier M, Hachet-Haas M, Galzi JL, Rognan D. Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J. Med. Chem. 50(6), 1294-1303 (2007). (Pubitemid 46504976)
80. Nowak M, Kolaczkowski M, Pawlowski M, Bojarski AJ. Homology modeling of the serotonin 5-HT1A receptor using automated docking of bioactive compounds with defined geometry. J. Med. Chem. 49(1), 205-214 (2006). (Pubitemid 43077334)
81. Tikhonova IG, Sum CS, Neumann S et al. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J. Med. Chem. 51(3), 625-633 (2008). (Pubitemid 351252290)
82. Cavasotto CN, Phatak SS. Homology modeling in drug discovery: current trends and applications. Drug Discov. Today 14(13-14), 676-683 (2009).
83. Costanzi S, Tikhonova IG, Harden TK, Jacobson KA. Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. J. Comput. Aided Mol. Des. 23(11), 747-754 (2009).
84. Levoin N, Calmels T, Poupardin-Olivier O et al. Refined docking as a valuable tool for lead optimization: application to histamine H3 receptor antagonists. Arch. Pharm. (Weinheim) 341(10), 610-623 (2008).
85. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454(7201), 183-187 (2008). (Pubitemid 351969893)
86. Bhattacharya S, Hall SE, Vaidehi N. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors. J. Mol. Biol. 382(2), 539-555 (2008).
87. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, Elling CE. Molecular mechanism of 7TM receptor activation - a global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 46, 481-519 (2006). (Pubitemid 43271198)
88. Sela I, Golan G, Strajbl M et al. G protein coupled receptors - in silico drug discovery and design. Curr. Top. Med. Chem. 10(6), 638-656 (2010).
89. Berkhout TA, Blaney FE, Bridges AM et al. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J. Med. Chem. 46(19), 4070-4086 (2003). (Pubitemid 37122451)
90. Carter PH, Tebben AJ. Chapter 12. The use of receptor homology modeling to facilitate the design of selective chemokine receptor antagonists. Methods Enzymol. 461, 249-279 (2009).
91. Hall SE, Mao A, Nicolaidou V et al. Elucidation of binding sites of dual antagonists in the human chemokine receptors CCR2 and CCR5. Mol. Pharmacol. 75(6), 1325-1336 (2009).
92. Sobhia ME, Singh R, Kare P, Chavan S. Rational design of CCR2 antagonists: a survey of computational studies. Expert Opin. Drug Discov. 5(6), 543-557 (2010).
93. Vaidehi N, Schlyer S, Trabanino RJ et al. Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J. Biol. Chem. 281(37), 27613-27620 (2006). (Pubitemid 44401786)
94. Wise EL, Duchesnes C, da Fonseca PC, Allen RA, Williams TJ, Pease JE. Small molecule receptor agonists and antagonists of CCR3 provide insight into mechanisms of chemokine receptor activation. J. Biol. Chem. 282(38), 27935-27943 (2007). (Pubitemid 47529544)
95. Deng Q, Frie JL, Marley DM et al. Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. Bioorg. Med. Chem. Lett. 18(18), 4963-4967 (2008).
96. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 29(1), 291-325 (2000). (Pubitemid 30599596)
97. Luci DK, Ghosh S, Smith CE et al. Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment. Bioorg. Med. Chem. Lett. 17(23), 6489-6492 (2007). (Pubitemid 350026338)
98. Kinney WA, Almond Jr HR, Qi J et al. Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew. Chem. Int. Ed. Engl. 41(16), 2940-2944 (2002). (Pubitemid 34966554)
99. Costanzi S, Tikhonova IG, Ohno M et al. P2Y1 antagonists: combining receptor-based modeling and QSAR for a quantitative prediction of the biological activity based on consensus scoring. J. Med. Chem. 50(14), 3229-3241 (2007). (Pubitemid 47065972)
100. Aqvist J, Medina C, Samuelsson JE. A new method for predicting binding affinity in computer-aided drug design. Protein Eng. 7(3), 385-391 (1994). (Pubitemid 24063137)
101. Li G, Aschenbach LC, He H, Selley DE, Zhang Y. 14-O-Heterocyclic- substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies. Bioorg. Med. Chem. Lett. 19(6), 1825-1829 (2009).
102. Widler L, Altmann E, Beerli R et al. 1-Alkyl-4-phenyl-6-alkoxy-1H- quinazolin- 2-ones: a novel series of potent calcium-sensing receptor antagonists. J. Med. Chem. 53(5), 2250-2263 (2010).
103. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 279(8), 7254-7263 (2004). (Pubitemid 38248875)
104. Yates AS, Doughty SW, Kendall DA, Kellam B. Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor. Bioorg. Med. Chem. Lett. 15(16), 3758-3762 (2005). (Pubitemid 41038973)
105. Kneissl B, Leonhardt B, Hildebrandt A, Tautermann CS. Revisiting automated G-protein coupled receptor modeling: the benefit of additional template structures for a neurokinin-1 receptor model. J. Med. Chem. 52(10), 3166-3173 (2009).
106. Larsson P, Wallner B, Lindahl E, Elofsson A. Using multiple templates to improve quality of homology models in automated homology modeling. Protein Sci. 17(6), 990-1002 (2009). (Pubitemid 351749205)
107. Martinelli A, Tuccinardi T. An overview of recent developments in GPCR modelling: methods and validation. Expert Opin. Drug Discov. 1(5), 459-476 (2006).
108. Mobarec JC, Filizola M. Advances in the development and application of computational methodologies for structural modeling of G-protein-coupled receptors. Expert Opin. Drug Discov. 3(3), 343-355 (2008). (Pubitemid 351425377)
109. Sali A, Blundell TL. Comparative protein modeling by satisfaction of spatial restraints. J. Mol. Biol. 234(3), 779-815 (1993). (Pubitemid 24007801)
110. Baker D, Sali A. Protein Structure prediction and structural genomics. Science 294(5540), 93-96 (2001). (Pubitemid 32952955)
111. Lesk, A. Introduction to Bioinformatics. Oxford University Press, Oxford, UK (2008).
112. Trabanino RJ, Hall SE, Vaidehi N, Floriano WB, Kam VW, Goddard WA III. First principles predictions of the structure and function of G-protein-coupled receptors: validation for bovine rhodopsin. Biophys. J. 86(4), 1904-1921 (2004). (Pubitemid 38524387)
113. Hallmen C, Wiese M. Molecular dynamics simulation of the human adenosine A3 receptor: agonist induced conformational changes of Trp243. J. Comput. Aided Mol. Des. 20(10-11), 673-684 (2006). (Pubitemid 46023929)
114. Patny A, Desai PV, Avery MA. Ligand-supported homology modeling of the human angiotensin II type 1 (AT1) receptor: insights into the molecular determinants of telmisartan binding. Proteins 65(4), 824-842 (2006). (Pubitemid 44772882)
115. Rivail L, Chipot C, Maigret B, Bestel I, Sicsic S, Tarek M. Large-scale molecular dynamics of a G protein-coupled receptor, the human 5-HT4 serotonin receptor, in a lipid bilayer. J. Mol. Struct: THEOCHEM 817(1-3), 19-26 (2007).
116. Tikhonova IG, Best RB, Engel S, Gershengorn MC, Hummer G, Costanzi S. Atomistic insights into rhodopsin activation from a dynamic model. J. Am. Chem. Soc. 130(31), 10141-10149 (2008).
117. Wolf S, Böckmann M, Höweler U, Schlitter J, Gerwert K. Simulations of a G protein-coupled receptor homology model predict dynamic features and a ligand binding site. FEBS Letters 582(23-24), 3335-3342 (2008).
118. Chipot C. Milestones in the activation of G protein-coupled receptor. Insights from molecular-dynamics simulations into the human cholcystokinin receptor-1. J. Chem. Theory Comput. 4(12), 2150-2159 (2008).
119. Khafizov K, Lattanzi G, Carloni P. G protein inactive and active forms investigated by simulation methods. Proteins 75(4), 919-930 (2009).
120. Provasi D, Filizola M. Putative active states of a prototypic g-protein-coupled receptor from biased molecular dynamics. Biophys. J. 98(10), 2347-2355 (2010).
121. Evers A, Klebe G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 47(22), 5381-5392 (2004). (Pubitemid 39382788)
122. Bissantz C, Schalon C, Guba W, Stahl M. Focused library design in GPCR projects on the example of 5-HT(2c) agonists: comparison of structure-based virtual screening with ligand-based search methods. Proteins 61(4), 938-952 (2005). (Pubitemid 41753164)
123. Köppen H. Virtual screening - what does it give us? Curr. Opin. Drug Discov. Devel. 12(3), 397-407 (2009).
124. Ligand Design for G Protein-Coupled Receptors. Rognan D (Ed.).Wiley-VCH, Weinheim, Germany (2006).